Study guide

13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations

WHNP-BC Women's Health Nurse Practitioner Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction: About the WHNP-BC Exam

WHNP-BC Exam Facts, Blueprint & Study Plan

2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening

1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening

3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention

2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites

4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers

3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers

5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility

4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies

6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy

5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion

7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health

6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis

8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care

7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction

9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care

8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy

10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth

9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency

11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions

10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn

12 Chapter 11: Intrapartum Principles & Fetal Surveillance

11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies

13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications

12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs

14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions

13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold

15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders

14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders

16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health

15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis

17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care

16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care

18 Chapter 17: Assessment, Diagnostic Testing & Interpretation

17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities

19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing

18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation

20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities

19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care

13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations

Key Takeaways Explain This Topic AI

Cardiovascular disease (CVD) is the leading cause of mortality in women in the United States, claiming more female lives each year than all forms of cancer combined, with distinct pathophysiology including microvascular dysfunction and arterial dissection.

The 2025 AHA/ACC guideline keeps the 2017 categories: Normal (<120/<80 mmHg), Elevated (120–129/<80 mmHg), Stage 1 Hypertension (130–139/80–89 mmHg), and Stage 2 Hypertension (≥140/≥90 mmHg); non-pharmacologic lifestyle interventions (DASH diet, sodium <1,500 mg/day, weight reduction, aerobic exercise) are foundational across all categories.

First-line pharmacotherapy for non-pregnant women includes thiazide diuretics (chlorthalidone preferred), dihydropyridine calcium channel blockers (amlodipine), and ACE inhibitors or ARBs, with combination therapy from two distinct classes recommended for Stage 2 hypertension.

ACE inhibitors and ARBs are strictly contraindicated during pregnancy and in women of childbearing potential without reliable contraception due to severe fetotoxicity (fetal renal dysgenesis, oligohydramnios, skull hypoplasia, neonatal renal failure, Potter sequence, and death); safe alternatives for women planning pregnancy include labetalol, extended-release nifedipine, and methyldopa.

Women frequently experience atypical acute coronary syndromes characterized by non-chest pain symptoms—profound unaccustomed fatigue, dyspnea, nausea, epigastric distress, and jaw or interscapular pain—as well as non-obstructive etiologies like microvascular coronary dysfunction (MCD), spontaneous coronary artery dissection (SCAD), and MINOCA, leading to diagnostic delays and higher in-hospital mortality.

Last updated: October 2026

Cardiovascular Disease Epidemiology in Women

Cardiovascular disease (CVD) is the leading cause of mortality among women in the United States, responsible for approximately 1 in every 3 to 4 female deaths and claiming more lives annually than all forms of cancer combined. Historically mischaracterized as a predominantly male condition, female cardiovascular disease has suffered from diagnostic biases, systematic underrepresentation in clinical trials, and clinical disparities in triage and the delivery of guideline-directed medical therapies.

Premenopausal women benefit from endogenous ovarian estrogen, which enhances vascular endothelial function, promotes endothelial nitric oxide synthase (eNOS) activity, maintains arterial compliance, and preserves a favorable lipoprotein profile. During the perimenopausal transition and postmenopause, the loss of circulating 17-beta-estradiol triggers arterial stiffening, upregulation of the renin-angiotensin-aldosterone system (RAAS), increased sympathetic vascular tone, central redistribution of adipose tissue into visceral depots, and adverse lipid remodeling. Consequently, cardiovascular risk accelerates sharply after menopause, rapidly narrowing the historical morbidity and mortality gap between females and males.

Blood Pressure Classification & ACC/AHA Diagnostic Thresholds

Hypertension is the most common modifiable risk factor for myocardial infarction, heart failure, and stroke in women. The 2025 AHA/ACC high blood pressure guideline (August 2025) keeps the 2017 categories:

  • Blood Pressure Category Systolic BP (mmHg) Diastolic BP (mmHg) Initial Clinical Strategy
  • Normal <120 and <80 Promote optimal lifestyle habits; reassess annually
  • Elevated 120–129 and <80 Non-pharmacologic lifestyle therapy; reassess in 3–6 months

Stage 1 Hypertension 130–139 or 80–89 Lifestyle therapy; add medication if clinical CVD, diabetes, CKD, or 10-year PREVENT risk ≥7.5%, or if BP stays ≥130/80 after 3–6 months of lifestyle change

Stage 2 Hypertension ≥140 or ≥90 Lifestyle therapy plus 2 first-line drugs of different classes, preferably as a single-pill combination

Severe Hypertension (replaces 'hypertensive urgency') >180 and/or >120 Assess for acute target-organ damage; if present, it is a hypertensive emergency

The general treatment goal is <130/80 mmHg . Accurate clinical diagnosis requires standardized measurement: seated quietly for ≥5 minutes with feet flat, back supported, arm at heart level, and an appropriately sized cuff. Confirmation requires averaging ≥2 readings across ≥2 separate clinical encounters, or ambulatory/home blood pressure monitoring.

Non-Pharmacologic Lifestyle Modifications

Lifestyle modification represents the foundation of hypertension prevention and management across all blood pressure categories:

DASH Diet: High in fruits, vegetables, whole grains, and low-fat dairy with reduced saturated fat; lowers systolic BP by ~11 mmHg in hypertensive individuals.

Sodium Restriction: Target <1,500 mg/day (or a minimum reduction of 1,000 mg/day); reduces systolic BP by ~5–6 mmHg.

Physical Activity: ≥150 min/week moderate-intensity aerobic exercise (or 75 min vigorous) plus dynamic resistance training 2–3 days/week; lowers systolic BP by ~4–8 mmHg.

Weight Reduction: Aim for BMI 18.5–24.9 kg/m²; yields ~1 mmHg systolic BP drop per kilogram lost in overweight individuals.

Alcohol: The 2025 guideline names abstinence as the optimal goal; women who drink should keep intake to ≤1 standard drink (14 g ethanol) per day.

Potassium Intake: Target 3,500–5,000 mg/day through dietary sources (unless contraindicated by chronic kidney disease or hyperkalemia).

Pharmacologic Management & Reproductive Safety

When pharmacotherapy is indicated in non-pregnant women, four first-line drug classes are recommended:

Thiazide Diuretics: Chlorthalidone (12.5–25 mg daily) is preferred over hydrochlorothiazide (HCTZ; 25–50 mg daily) due to longer half-life (40–60 hours) and proven cardiovascular event reduction. Adverse effects include hypokalemia, hyponatremia, and hyperuricemia.

Calcium Channel Blockers (CCBs): Dihydropyridines (amlodipine 2.5–10 mg daily; nifedipine ER 30–60 mg daily) inhibit vascular smooth muscle calcium influx, causing peripheral vasodilation. A common adverse effect is dose-dependent pedal edema.

ACE Inhibitors: Agents like lisinopril (10–40 mg daily) block angiotensin II conversion; common adverse effects include dry bradykinin cough (affecting up to 20% of women) and angioedema.

Angiotensin Receptor Blockers (ARBs): Agents like losartan (50–100 mg daily) selectively block AT1 receptors without causing bradykinin cough, serving as first-line alternatives for patients intolerant to ACE inhibitors.

In Black patients without heart failure or CKD, initial monotherapy should include a thiazide or CCB rather than an ACE inhibitor or ARB. For Stage 2 hypertension (especially BP >20/10 mmHg over goal), prompt initiation of two first-line agents of different classes is recommended.

Important

Black Box Warning & Reproductive Fetotoxicity of ACE Inhibitors and ARBs: ACE inhibitors and ARBs are contraindicated in pregnancy (FDA boxed warning for fetal toxicity). Second- and third-trimester exposure causes fetal renal tubular dysgenesis, oligohydramnios, Potter sequence (craniofacial compression, limb contractures, pulmonary hypoplasia), neonatal anuria, calvarial skull hypoplasia, and perinatal death.

Women of childbearing potential must use reliable contraception if prescribed ACEi/ARBs. If planning pregnancy or upon pregnancy confirmation, discontinue immediately. Safe first-line agents in reproductive-age women planning pregnancy or with chronic hypertension in pregnancy are:

Oral Labetalol: 100–400 mg PO BID/TID (combined alpha/beta-blocker; avoid in active asthma or severe bradycardia).

Extended-Release Nifedipine: 30–90 mg PO daily (dihydropyridine CCB; avoid sublingual administration).

Methyldopa: 250–500 mg PO BID/TID (central alpha-2 agonist; sedating, long-established safety record). (Note: Atenolol is avoided in pregnancy due to association with fetal growth restriction).

Sex-Specific Coronary Artery Disease Mechanisms

Pathophysiology of coronary artery disease (CAD) in women frequently differs from the discrete obstructive epicardial stenosis classic in men:

Microvascular Coronary Dysfunction (MCD): Structural remodeling and endothelial impairment in resistance arterioles (<500 µm). Conventional angiography reveals non-obstructive or "normal" vessels despite objective myocardial ischemia and angina. Diagnosis requires coronary reactivity testing demonstrating reduced coronary flow reserve (CFR <2.0).

Spontaneous Coronary Artery Dissection (SCAD): Non-atherosclerotic separation of the arterial tunica media with intramural hematoma formation compressing the lumen. Over 90% of cases occur in women (mean age 45–53 years), with high incidence postpartum, during pregnancy, and in women with fibromuscular dysplasia (FMD; present in up to 70%). Conservative medical therapy (beta-blockers, aspirin) is preferred over percutaneous coronary intervention (PCI) in stable patients, as stenting often propagates dissection flaps.

Myocardial Infarction with Non-Obstructive Coronary Arteries (MINOCA): Clinical MI criteria without angiographic stenosis ≥50%. Etiologies include plaque erosion, vasospasm, microvascular disease, SCAD, and takotsubo cardiomyopathy. MINOCA is twice as prevalent in women compared to men.

Female-Specific Clinical Presentations of Acute Myocardial Infarction

Women presenting with acute myocardial infarction (AMI) are significantly more likely than men to exhibit non-chest pain ("atypical") symptoms:

Dyspnea: The most common non-chest pain symptom in females.

Profound Unaccustomed Fatigue: Overwhelming exhaustion often preceding the event by days or weeks.

Gastrointestinal Symptoms: Epigastric distress, indigestion, nausea, and vomiting, frequently misattributed to GI illness.

Non-Precordial Radiation: Tightness, burning, or aching in the jaw, neck, throat, interscapular back, or shoulders.

Autonomic Signs: Diaphoresis, presyncope, severe insomnia, and acute anxiety.

Atypical presentations frequently lead to triage delays, deferred ECGs and troponin testing, lower cardiac catheterization rates, underutilization of guideline-directed therapies, and higher in-hospital mortality in women.